NDA 011719 · Hospira
Methotrexate Preservative Free
Methotrexate Sodium · Injection
OrphanLast checked: Nov 20, 2026Latest source record: Oct 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1959
Aug 10, 1959
Approved uses
3
Original approval plus efficacy supplements
Registered trials
2,087
570 Phase 3, 211 recruiting
FAERS reports
487,627
358,960 serious, 38,300 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: EMBRYO-FETAL TOXICITY, HYPERSENSITIVITY REACTIONS, BENZYL ALCOHOL TOXICITY, and OTHER SERIOUS ADVERSE REACTIONS • Methotrexate Injection can cause embryo-fetal toxicity, including fetal death. For non-neoplastic diseases, Methotrexate Injection is contraindicated in pregnancy. Advise females and males of reproductive potential to use effective contraception [see Contraindications (4) , Warnings and Precautions (5.1) , and Use in Specific Populations (8.1 , 8.3) ] . • Methotrexate Injection is contraindicated in patients with a history of severe hypersensitivity reactions to methotrexate, including anaphylaxis [see Contraindications (4) and Warnings and Precautions (5.2) ]. • Formulations with benzyl alcohol can cause severe central nervous toxicity or metabolic acidosis. Use only preservative-free Methotrexate Injection for treatment of neonates or low birth weight infants and...
What it is approved for
From the label in effect Oct 29, 2026.
Methotrexate Injection is a folate analog metabolic inhibitor indicated for: • The following neoplastic diseases for the: o Treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a combination chemotherapy regimen. ( 1.1 ) o Prophylaxis and treatment of adult and pediatric patients with meningeal leukemia. ( 1.2 ) o Treatment of adult and pediatric patients with non-Hodgkin lymphoma. ( 1.3 ) o Treatment of adult and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. ( 1.4 ) o Treatment of adults with breast cancer as part of a combination chemotherapy regimen. ( 1.5 ) o Treatment of adults with squamous cell carcinoma of the head and neck as a single agent. ( 1.6 ) o Treatment of adults with gestational trophoblastic neoplasia as part of a combination chemotherapy regimen. ( 1.7 ) • Treatment of adults with rheumatoid arthritis (RA). ( 1.8 ) • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA). ( 1.9 ) • Treatment of adults with severe psoriasis. ( 1.10 ) 1.1 Acute Lymphoblastic Leukemia Methotrexate Injection is indicated for the treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen. 1.2 Meningeal Leukemia: Prophylaxis and Treatment Methotrexate Injection is indicated for the prophylaxis and treatment of meningeal leukemia in adult and pediatric patients. 1.3 Non-Hodgkin Lymphoma Methotrexate Injection is indicated for the treatment of adults and pediatric patients with non-Hodgkin lymphoma. 1.4 Osteosarcoma Methotrexate Injection is indicated for the treatment of adults and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. 1.5 Breast Cancer Methotrexate...
Mechanism: Methotrexate inhibits dihydrofolic acid reductase. Dihydrofolates must be reduced to tetrahydrofolates by this enzyme before they can be utilized as carriers of one-carbon groups in the synthesis of purine nucleotides and thymidylate. Therefore, methotrexate interferes with DNA synthesis, repair, and cellular replication. Actively proliferating tissues such as malignant cells, bone marrow, fetal cells, buccal and intestinal mucosa, and cells of the urinary bladder are in general more sensitive to this effect of methotrexate. The mechanism of action in rheumatoid arthritis, pJIA, and in...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 29, 2021 Supplement 131 · Efficacy LabelLetter
- Apr 7, 1988 Supplement 77 · Efficacy
- Aug 10, 1959 Original approval · Type 2 - New Active Ingredient
12 products under this application
- METHOTREXATE PRESERVATIVE FREE · METHOTREXATE SODIUM EQ 20MG BASE/2ML (EQ 10MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
- METHOTREXATE SODIUM · METHOTREXATE SODIUM EQ 100MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
- METHOTREXATE SODIUM PRESERVATIVE FREE · METHOTREXATE SODIUM EQ 1GM BASE/40ML (EQ 25MG BASE/ML) · INJECTABLE, INJECTION · Prescription · TE AP
- METHOTREXATE SODIUM · METHOTREXATE SODIUM EQ 2.5MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
- METHOTREXATE SODIUM · METHOTREXATE SODIUM EQ 50MG BASE/2ML (EQ 25MG BASE/ML) · INJECTABLE, INJECTION · Prescription · TE AP
- METHOTREXATE SODIUM PRESERVATIVE FREE · METHOTREXATE SODIUM EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
- METHOTREXATE LPF · METHOTREXATE SODIUM EQ 25MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
- METHOTREXATE PRESERVATIVE FREE · METHOTREXATE SODIUM EQ 500MG BASE/20ML (EQ 25MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
- METHOTREXATE SODIUM · METHOTREXATE SODIUM EQ 25MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
- METHOTREXATE PRESERVATIVE FREE · METHOTREXATE SODIUM EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
- METHOTREXATE SODIUM · METHOTREXATE SODIUM EQ 50MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
- METHOTREXATE SODIUM · METHOTREXATE SODIUM EQ 20MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Methotrexate" as an intervention, any sponsor and status, largest first.
- Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic LymphomaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT01190930 · 9,350 participants · Start Aug 11, 2010 · Primary completion Mar 31, 2019
Drug: Cyclophosphamide; Cytarabine and 8 more · For: Acute Lymphoblastic Leukemia; Adult B Lymphoblastic Lymphoma; Ann Arbor Stage I B Lymphoblastic Lymphoma and 7 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 243 sites in all
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03914625 · 6,720 participants (planned) · Start Jul 3, 2019 · Primary completion Sep 30, 2027
Drug: Asparaginase Erwinia chrysanthemi; Blinatumomab and 13 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Down Syndrome
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 228 sites in all
- International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
University Hospital Schleswig-HolsteinAcademic, hospital or other
NCT01117441 · 6,136 participants · Start Jun 2010 · Primary completion Dec 31, 2021
Drug: PEG-L-asparaginase; cyclophosphamide and 14 more · For: Leukemia
Sites: Randwick, Australia; Westmead, Australia; Dornbirn, Austria · 139 sites in all
- Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast CancerPivotal-lookingCompleted
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT00002582 · 6,000 participants (planned) · Start Jun 1993
Drug: CMF regimen; cyclophosphamide and 6 more · For: Breast Cancer
Sites: Birmingham, United Kingdom; Glasgow, United Kingdom
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03959085 · 5,951 participants (planned) · Start Oct 31, 2019 · Primary completion Mar 31, 2032
Drug: Blinatumomab; Calaspargase Pegol and 14 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Central Nervous System Leukemia and 2 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 231 sites in all
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive MutationsPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT02883049 · 5,949 participants · Start Feb 29, 2012 · Primary completion Dec 31, 2022
Drug: Clofarabine; Cyclophosphamide and 14 more · For: B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, BCR-ABL1-Like; Central Nervous System Leukemia and 1 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 239 sites in all
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00103285 · 5,377 participants · Start Apr 11, 2005 · Primary completion Dec 30, 2013
Drug: Cyclophosphamide; Cytarabine and 8 more · For: Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia
Sites: Birmingham, Alabama; Mobile, Alabama; Mesa, Arizona · 236 sites in all
- Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017Pivotal-lookingRecruiting
Martin SchrappeAcademic, hospital or other
NCT03643276 · 5,000 participants (planned) · Start Jul 15, 2018 · Primary completion Jul 14, 2028
Drug: Blinatumomab; Bortezomib and 17 more · For: Acute Lymphoblastic Leukemia, Pediatric
Sites: Sydney, Australia; Westmead, Australia; Graz, Austria · 115 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective93,085
- rheumatoid arthritis42,801
- arthralgia40,718
- off label use40,573
- pain39,635
- fatigue33,027
- nausea28,920
- joint swelling24,995
- drug intolerance24,515
- condition aggravated23,993
- headache23,450
- rash22,590
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 5,891 |
| 2005 | 5,584 |
| 2006 | 5,149 |
| 2007 | 8,029 |
| 2008 | 9,257 |
| 2009 | 9,418 |
| 2010 | 9,834 |
| 2011 | 10,985 |
| 2012 | 15,617 |
| 2013 | 17,734 |
| 2014 | 17,445 |
| 2015 | 21,279 |
| 2016 | 25,472 |
| 2017 | 32,187 |
| 2018 | 43,779 |
| 2019 | 40,975 |
| 2020 | 46,026 |
| 2021 | 30,926 |
| 2022 | 34,807 |
| 2023 | 32,370 |
| 2024 | 27,844 |
| 2025 | 23,597 |
| 2026 | 13,413 |
Recalls
2 FDA enforcement reports for this application.
Mar 15, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Jun 27, 2012 · Class II · Terminated
The affected lots of Carboplatin Injection, Cytarabine Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial....
Shortages
FDA's drug shortage list.
Current · updated Nov 9, 2026
Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38).
Current · updated Nov 9, 2026
Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) Multiple Dose Vial PREMIERProRx (NDC 61703-161-05). Other
Current · updated Nov 9, 2026
Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40).
Current · updated Nov 9, 2026
Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25).
Current · updated Nov 9, 2026
Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-10).
Current · updated Nov 9, 2026
Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41).
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Methotrexate Sodium (Methotrexate Sodium/PF)
2024 spending
$901K
Beneficiaries
18,556
59,947 claims
Per beneficiary
$49
$1.50 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,327,068 |
| 2021 | $1,357,555 |
| 2022 | $1,441,309 |
| 2023 | $843,319 |
| 2024 | $901,080 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate.
Kahlmann V, Janssen Bonás M, Moor CC, et al. · N Engl J Med 2025 · Clinical Trial, Phase IV, Equivalence Trial
- Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials.
Spencer RK, Jin JQ, Elhage KG, et al. · J Am Acad Dermatol 2023 · Letter, Network Meta-Analysis
- Medical treatment of uterine arteriovenous malformation: a systematic review and meta-analysis.
Rosen A, Chan WV, Matelski J, et al. · Fertil Steril 2021 · Comparative Study, Meta-Analysis
- Tocilizumab Monotherapy or Combined With Methotrexate for Rheumatoid Arthritis: A Randomized Clinical Trial.
Liu T, Wang L, Zhang X, et al. · JAMA Netw Open 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
Ridker PM, Everett BM, Pradhan A, et al. · N Engl J Med 2019 · Multicenter Study, Randomized Controlled Trial
- Pregnancy Outcomes Following Paternal Methotrexate Exposure: A Systematic Review and Meta-Analysis.
Uysal N, Yilmaz H, Gungor M, et al. · Birth Defects Res 2025 · Systematic Review, Meta-Analysis
Sponsor: Pfizer · Also marketed as Methotrexate Sodium, Methotrexate Sodium Preservative Free, Methotrexate Lpf
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.